Branches of biology

Global Genome Editing Market Segment Forecasts 2021-2028: Cell Line Engineering Dominates the Market - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021

The "Global Genome Editing Market Size, Share & Trends Analysis Report by Technology (CRISPR, ZFN, TALEN), by Delivery Method, by Application, by Mode, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genome Editing Market Size, Share & Trends Analysis Report by Technology (CRISPR, ZFN, TALEN), by Delivery Method, by Application, by Mode, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global genome editing market size is expected to reach USD 19.4 billion by 2028.
  • The market is expected to expand at a CAGR of 22.9% from 2021 to 2028.
  • Moreover, the Cas protein system is gaining traction in the development of point-of-care diagnostics, thereby driving investment flow in diagnostic applications
    China is reported to be the first country to have successfully transferred genetically edited cells into humans, to boost immunity and treat lung cancer, thereby driving the market
    Chapter 1 Genome Editing Market: Research Methodology
    Chapter 2 Genome Editing Market: Executive Summary
    Chapter 3 Genome Editing Market: Industry Outlook
    Chapter 4 Genome Editing Market: Technology Business Analysis
    Chapter 5 Genome Editing Market: Delivery Method Business Analysis
    Chapter 6 Genome Editing Market: Application Business Analysis
    Chapter 7 Genome Editing Market: End-Use Business Analysis
    Chapter 8 Genome Editing Market: Mode Business Analysis
    Chapter 9 Genome Editing Market: Regional Business Analysis
    Chapter 10 Genome Editing Market: Competitive Landscape

Insights on the Neurostimulation Devices Global Market to 2026 - Rise in Number of People Suffering from Hearing Loss is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021

Neurostimulation is used as a key element in neural prosthetics for hearing aids, artificial vision, artificial limbs, brain-machine interfaces, etc.

Key Points: 
  • Neurostimulation is used as a key element in neural prosthetics for hearing aids, artificial vision, artificial limbs, brain-machine interfaces, etc.
  • the growth in the neurostimulation devices market may be attributed to the increasing prevalence of chronic neuromuscular disorder and the rising adoption of these devices by the physicians.
  • However, stringent regulations of the neurostimulation devices and lack of skilled professionals for performing the surgeries might restrain the market growth during the given time frame.
  • The market is expected to surge in the coming years, due to the rise in the number of people, suffering from hearing loss and other related concerns.

Newron Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia

Retrieved on: 
Monday, September 6, 2021

Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the initiation of Study 008A, the first potentially pivotal study with evenamide in patients with schizophrenia.

Key Points: 
  • Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the initiation of Study 008A, the first potentially pivotal study with evenamide in patients with schizophrenia.
  • This study is part of Newrons Phase III evenamide clinical trial program that targets patients with schizophrenia experiencing worsening of psychosis on therapeutic doses of atypical antipsychotics, as well as treatment-resistant patients.
  • If successful, Newron believes the study would qualify as the first adequate and well-controlled (pivotal) study with evenamide in patients with schizophrenia who are inadequate responders to antipsychotics.
  • Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

Valbiotis Announces the Completion of Recruitment for the Phase II HEART Clinical Study Conducted With TOTUM•070 in Hypercholesterolemia, a Risk Factor for Cardiovascular Disease

Retrieved on: 
Monday, September 6, 2021

In line with its development plan, Valbiotis confirms that the results of the HEART study will be available in the second quarter of 2022.

Key Points: 
  • In line with its development plan, Valbiotis confirms that the results of the HEART study will be available in the second quarter of 2022.
  • The HEART clinical study is a multicenter, international, randomized, placebo-controlled, double-blind study involving 120 people with untreated moderate hypercholesterolemia between 130 and 190 mg/dL.
  • The primary endpoint of the HEART study is the reduction of blood LDL-cholesterol levels, a risk factor for cardiovascular disease and in particular atherosclerosis, and it has several secondary objectives of interest.
  • The medical need is real: according to the WHO, nearly 40% of the world's adult population has high cholesterol, a well-known cardiovascular risk factor.

Metabolic Changes in Plasma and Immune Cells Are Associated with COVID-19 Severity and May Predict Patient Survival, Institute for Systems Biology (ISB) Study Shows

Retrieved on: 
Monday, September 6, 2021

Researchers from Institute for Systems Biology (ISB), Fred Hutchinson Cancer Research Center and other organizations have uncovered underlying metabolic changes that regulate how immune cells react to COVID-19.

Key Points: 
  • Researchers from Institute for Systems Biology (ISB), Fred Hutchinson Cancer Research Center and other organizations have uncovered underlying metabolic changes that regulate how immune cells react to COVID-19.
  • After examining the blood samples from nearly 200 COVID-19 patients, researchers have uncovered underlying metabolic changes that regulate how immune cells react to the disease.
  • These changes are associated with disease severity and could be used to predict patient survival.
  • The deeper understanding gained here may eventually lead to better therapies that can more precisely target the most problematic immune or metabolic changes.

Antech offers first predictive test and proactive plan of care for feline CKD

Retrieved on: 
Monday, September 6, 2021

Royal Canin's Renal Support Early Consultrounds out Antech's renal portfolio, creating a Proactive Care Plan for feline CKD.

Key Points: 
  • Royal Canin's Renal Support Early Consultrounds out Antech's renal portfolio, creating a Proactive Care Plan for feline CKD.
  • "Now that veterinarians can predict the onset of disease up to two years before it occurs, we absolutely need new early care strategies.
  • "The ability to predict disease allows for a new care pathway for feline CKD that represents an improved standard of care," said Todd East DVM, Director of Veterinary Affairs at Royal Canin.
  • Antech Imaging Services (AIS) offers high-quality imaging decision support via a team of over 100 board-certified specialists and reliable image storage solutions enhanced by constant technological innovation.

Dr Joseph Okai, MD Joins Lifestream Health

Retrieved on: 
Monday, September 6, 2021

BOWIE, Md., Sept. 6, 2021 /PRNewswire-PRWeb/ --Dr. Joseph Okai is originally from Laurel, Maryland.

Key Points: 
  • BOWIE, Md., Sept. 6, 2021 /PRNewswire-PRWeb/ --Dr. Joseph Okai is originally from Laurel, Maryland.
  • Dr. Okai utilizes a multidisciplinary approach to treating pain which appreciates that both physical and emotional health are both vital to the outcomes of his patients.
  • Dr. Okai joined the Lifestream team after the completion of his training and he is excited about the opportunity to treat the members of the community that he considers his home.
  • Lifestream Health Center has been serving the Bowie/Baltimore-Washington D.C. Metropolitan area since 2000, when the practice was established by Dr. Robert Lyles.

DGAP-News: Newron Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia

Retrieved on: 
Monday, September 6, 2021

Newron plans to randomize at least 200 patients in study centers in Europe, Asia and Latin America.

Key Points: 
  • Newron plans to randomize at least 200 patients in study centers in Europe, Asia and Latin America.
  • This study is part of Newron's Phase III evenamide clinical trial program that targets patients with schizophrenia experiencing worsening of psychosis on therapeutic doses of atypical antipsychotics, as well as treatment-resistant patients.
  • If successful, Newron believes the study would qualify as the first adequate and well-controlled (pivotal) study with evenamide in patients with schizophrenia who are inadequate responders to antipsychotics.
  • Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

DGAP-News: Cannovum AG starts European cannabis expansion with founding of Cannovum Iberia LDA

Retrieved on: 
Monday, September 6, 2021

Cannovum AG (stock exchanges Dsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has started its European cannabis expansion with its subsidiary, Cannovum Health eG.

Key Points: 
  • Cannovum AG (stock exchanges Dsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has started its European cannabis expansion with its subsidiary, Cannovum Health eG.
  • The first step for this was founding Cannovum Iberia LDA, a joint venture between Cannovum and Portuguese entrepreneurs from the cannabis industry.
  • Cannovum Iberia will initially distribute cannabis pharmaceuticals to pharmacies in Portugal.
  • "We have reached the first milestone and successfully completed the founding process of Cannovum Iberia LDA.

Global Medical Cannabis Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021

Cannabis is a psychoactive drug that is derived from the cannabis plant of the Cannabaceae family.

Key Points: 
  • Cannabis is a psychoactive drug that is derived from the cannabis plant of the Cannabaceae family.
  • Owing to its therapeutic benefits, cannabis has been approved for medical use in numerous countries, with varying degrees of legal restrictions.
  • Clinical trials, research and development (R&D) activities and commercialization of cannabis-based indications are further expected to catalyze the growth of the market.
  • As a result, increasing disposable incomes are projected to create a positive impact on the demand for medical cannabis.